These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
121 related articles for article (PubMed ID: 16943414)
1. Acute pancreatitis. Famularo G; Minisola G; De Simone C N Engl J Med; 2006 Aug; 355(9):961; author reply 961. PubMed ID: 16943414 [No Abstract] [Full Text] [Related]
2. Does gabexate mesilate affect serum concentrations of acute phase proteins after endoscopic retrograde cholangiopancreatography examination? Pezzilli R; Gabbrielli A; Labate AM; D'Alessio P; Barakat B; Costamagna G; Dibenedetti F; Massa M; Merlini G; d'Eril GM Hepatogastroenterology; 2003; 50(51):851-5. PubMed ID: 12828103 [TBL] [Abstract][Full Text] [Related]
3. Protease inhibitors for prevention of ERCP pancreatitis: can we afford the price of success? Ziebert JJ; Bjorkman DJ Am J Gastroenterol; 1997 Jun; 92(6):1067-8. PubMed ID: 9177543 [No Abstract] [Full Text] [Related]
4. Antisecretory vs. antiproteasic drugs in the prevention of post-ERCP pancreatitis: the evidence-based medicine derived from a meta-analysis study. Andriulli A; Caruso N; Quitadamo M; Forlano R; Leandro G; Spirito F; De Maio G JOP; 2003 Jan; 4(1):41-8. PubMed ID: 12555015 [TBL] [Abstract][Full Text] [Related]
5. Comparison of two dosing regimens of gabexate in the prophylaxis of post-ERCP pancreatitis. Masci E; Cavallini G; Mariani A; Frulloni L; Testoni PA; Curioni S; Tittobello A; Uomo G; Costamagna G; Zambelli S; Macarri G; Innocenti P; Dragonetti C; Am J Gastroenterol; 2003 Oct; 98(10):2182-6. PubMed ID: 14572565 [TBL] [Abstract][Full Text] [Related]
7. Nafamostat mesilate for prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis: a prospective, randomized, double-blind, controlled trial. Yoo KS; Huh KR; Kim YJ; Kim KO; Park CH; Hahn T; Park SH; Kim JH; Park CK; Kwon YJ; Lehman GA Pancreas; 2011 Mar; 40(2):181-6. PubMed ID: 21206331 [TBL] [Abstract][Full Text] [Related]
8. Making sense of meta-analyses on the use of protease inhibitors for the prevention of post-ERCP pancreatitis. Baron TH; Itoi T Gastrointest Endosc; 2011 Apr; 73(4):707-9. PubMed ID: 21457815 [No Abstract] [Full Text] [Related]
9. Gabexate for the prevention of pancreatic damage related to endoscopic retrograde cholangiopancreatography. Gabexate in digestive endoscopy--Italian Group. Cavallini G; Tittobello A; Frulloni L; Masci E; Mariana A; Di Francesco V N Engl J Med; 1996 Sep; 335(13):919-23. PubMed ID: 8786777 [TBL] [Abstract][Full Text] [Related]
10. Efficacy of postprocedure administration of gabexate mesylate in the prevention of post-ERCP pancreatitis: a randomized, controlled, multicenter study. Manes G; Ardizzone S; Lombardi G; Uomo G; Pieramico O; Porro GB Gastrointest Endosc; 2007 Jun; 65(7):982-7. PubMed ID: 17531632 [TBL] [Abstract][Full Text] [Related]
11. Antiproteases in the treatment of acute pancreatitis. Kitagawa M; Hayakawa T JOP; 2007 Jul; 8(4 Suppl):518-25. PubMed ID: 17625309 [No Abstract] [Full Text] [Related]
12. Antiproteasic agents in the prevention of post-ERCP pancreatitis: rationale for use and clinical results. Cavallini G; Frulloni L JOP; 2003 Jan; 4(1):75-82. PubMed ID: 12555019 [No Abstract] [Full Text] [Related]
14. Gabexate for the prevention of pancreatic damage related to endoscopic retrograde cholangiopancreatography. Schneider J; Barkin J Gastrointest Endosc; 1997 May; 45(5):447-8. PubMed ID: 9165340 [No Abstract] [Full Text] [Related]
15. Gabexate in the prophylaxis of post-ERCP pancreatitis: a meta-analysis of randomized controlled trials. Zheng M; Chen Y; Yang X; Li J; Zhang Y; Zeng Q BMC Gastroenterol; 2007 Feb; 7():6. PubMed ID: 17295917 [TBL] [Abstract][Full Text] [Related]
16. Frequency of post-ERCP pancreatitis in a single tertiary referral centre without and with routine prophylaxis with gabexate: a 6-year survey and cost-effectiveness analysis. Testoni PA; Mariani A; Masci E; Curioni S Dig Liver Dis; 2006 Aug; 38(8):588-95. PubMed ID: 16731060 [TBL] [Abstract][Full Text] [Related]